understand our process

Discover how we obtain the best antibodies

A step by step demonstration of how we get the best candidates in just 21 days. Scroll your way through !

Step 01

Target characterization

We first characterize your target: retrieve or model 3D structure, competitive analysis, suitable regions for antibody binding. Then we choose the epitope(s) with you.

Step 02

Binders design

We find antibodies binding to the chosen epitope. These antibodies can be designed completely in silico or they can come from different sources: your own antibody bank, MAbSilico’s antibody bank, NGS of enriched immune repertoires, NGS of patients repertoires.

Step 03

Leads optimization

The binders are optimized for affinity, developability, low off-targets number, diversity. The selected final candidates are your leads, ready for functional validations and pre-clinical studies.

Step 04

Antibodies candidates

The leads sequences are obtained by gene synthesis, cloned to be expressed as full-length IgGs, ready to be tested in binding (Cytometry, HTRF, BLI...) and in your functional assays.

Success keys

Get antibodies binding to a determined region on your target


Get antibodies with nano-molar affinity


Get antibodies optimized and ready for pre-clinical developmement

This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
How do we go further

Technologies we use

MAbSilico enables our partners to accelerate and improve the success rate in identifying the best lead candidates. Our epitope-driven antibody design uses a multi-parameter approach to design antibodies while taking into account affinity, specificity, developability, and safety all at once.

De Novo design

Design new leads against your target.

Target structural modeling
If the 3D structure of your target is not available, we can model it, even with very low sequence identity.
Target surface characterization
Identify the most promising regions for antibody binding.
Epitope mapping
Know where your antibody binds, to trigger the desired biological function and strengthen your IP.
Affinity prediction and maturation
Start the project with an antibody having the ideal affinity for your goal.
Framework design
Find the best frameworks for your CDRs in the targeted species.
Developability optimization
Assess the solubility and the aggregation risk, identify the potential PTMs and the immunogenic patches.
OSE Immunotherapeutics
TIGIT: epitope-driven designed with nM affinity

Computational epitope-driven antibody design against TIGIT with nM affinity:
TIGIT is a major immune checkpoint target to develop new drugs for cancer treatment. More than 10 biotech and pharma companies are trying to design the drug for tomorrow’s breakthrough treatment. While 9 clinical trials are ongoing, more than 1000 of anti-TIGIT antibodies are described in patents. MAbSilico’s goal was to design, from a non-paired scFv naïve bank, antibodies directed against a predetermined epitope of TIGIT with nanomolar affinity.

"We discovered new drug candidates in a couple of days compared to several months"

Testimonial from Nicolas Poirier, CEO of OSE: What was impressive is the high success rate higher than 50%, compared to the usual 5%, which allows our company to accelerate, to decrease the risks and to develop new immunotherapies for the patients."

Out of trillions of possibilities, MAbSilico managed to design, in 21 days, 300 antibodies among which 90% were validated with bioassays to bind TIGIT. Computational affinity maturation was then performed on the best candidates and BLI showed that sub-nanomolar affinity was reached. During the design and optimization, MAbSilico evaluated the criteria to limit cross-reactivity and avoid liability issues, in order to get the best candidates fulfilling developability specifications and freedom-to-operate.

Highlights of computational epitope-driven antibody design against TIGIT
Read more

Antibody optimization

Optimize your hits.

Find the best human framework for your CDRs. Can be applied to other species.
Affinity maturation
Increase or decrease your antibody’s affinity for its target.
Cross-species binding
Assess the binding of your antibody to model species orthologs.
Developability maturation
Optimize the solubility of your antibody, remove potential PTMs and immunogenic patches.
Confidential programs

Antibody characterization

Epitope mapping
Know where your antibody binds, to trigger the desired biological function and strengthen your IP.
Wichita University
Epitope mapping of an anti-FSH antibody

The anti-FSH antibody was docked on the 3D structure of the FSH, and the epitope predicted. Experimental validation was tricky, since FSH is not a membrane protein, and is a notoriously difficult protein to produce. Indeed, FSH is constituted of two chains (⍺ and ß), assembled and linked by disulfide bonds. To validate the epitope prediction, a construct was designed, including the two chains fused to a trans-membrane helix domain, resulting in the membrane anchorage of the hormone. We validated that the antibody binds with high affinity to this construct. Mutations were then introduced at the positions predicted to belong to the epitope of the antibody. We showed experimentally that binding to the mutants was decreased or abolished, validating our predictions.

Results were presented at the conference “Writing the Future of Drug Discovery”.

Read more
OSE Immunotherapeutics
Epitope mapping of an anti-ChemR23 antibody

3D structure of the ChemR23 receptor, a GPCR involved in Inflammatory Bowel Disease, was modeled from that of angiotensin receptor. The antibody developed by OSE Immunotherapeutics was docked on this model, and we predicted its epitope. Experimental validation of the epitope was performed using enzyme-linked immunosorbent assay (ELISA) binding assay. Results were published in Science Advances.

More information about ChemR23: https://www.ose-immuno.com/en/our-products/ose-230-modular/

Read more

Other biologics

Our technologies can be used for scaffold protein and peptides

(Renseigner les outils dans l'éditeur)
New Use cases to come soon !

Get in touch !

Drop us a line if you want to know more about our technology or if you are willing to talk about your projects. We are always keen on discussing science!

Contact us